Trump threatens 100% tariffs on imported generic drugs, raising reshoring questions

While President Donald Trump has repeatedly claimed that he is working to lower the cost of prescription drugs, advocates for patients on Wednesday expressed alarm over the Republican’s plan to impose significant tariffs on imported generic medication. “Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after […] The post New Trump tariffs to block Indian, Chinese generic drugs sourcing appeared first on Asia Times.

Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact companies with substantial US revenue exposure. Analysts suggest investors should now focus on domestically oriented Indian pharmaceutical firms. The Nifty Pharma index saw a notable decrease, while the benchmark Nifty 50 also fell. Negotiations are expected given India's vital role in supplying affordable medicines to the US.

President Donald Trump is threatening to impose a 100% tariff on imported generic medications, which could raise costs for Americans unless drugmakers can move production to the U.S. by August 2028. In his latest swipe at the pharmaceutical industry, Trump posted on Truth Social Tuesday that imported generic medicines would be subject to a 100% tariff beginning in August 2028 that would rise to 200% in August 2029. The president’s goal is to reshore production “to protect the people of the United States” even though American consumers would likely end up paying much higher costs, as generic drugs make up more than 90% of prescriptions.  But experts caution that, as with some of Trump’s past tariff threats, there are more questions than answers right now about whether that timeline is feasible for reshoring production for drugmakers, how the tariff would be applied, and whether the president is willing to negotiate. What’s more, the Trump administration has yet to make a formal executive order or issue an official policy implementing tariffs on generic medines. That’s why more details are needed, according to the Association for Accessible Medicines, which represents generic drugmakers. And there may be alternative legislative and regulatory solutions that could help address market deficiencies, president and CEO John Murphy III said in a statement to Politico.  “We need to understand more the specifics of the policy, but the generics industry is committed to pursuing policies that support and stabilize both the industry and the access necessary to ensure patients have reliable options for affordable medicines,” Murphy said.  Still, the threat of tariffs has been enough to unnerve traders. Shares of various European and Asian companies that manufacture generic drugs fell as much as 4.3% on Wednesday, as The Wall Street Journal reported. WILL THIS MEAN HIGHER COSTS FOR CONSUMERS? Whether idle or real, Trump’s latest tariff threat could upend the generic drug industry—and materially shock a current regime that’s ensured these medicines are more affordable in the U.S. than in many other countries, as Jeremy Leonard, managing director of global industry services at Oxford Economics, told Bloomberg. “The main effect is likely to be higher costs and supply disruption rather than a quick move of production to the U.S.” While drugmakers enjoy years of exclusivity for brand-name drugs to account for the years of costly research and development that allow them to charge higher prices for the medicines, that’s not a luxury shared by generic drugmakers. Rather, after patents have expired and a proven market has been identified, makers of generic medicines enter the market and compete largely on price.  Thinner margins for generic drugs mean that tariffs of 100% or 200% would be very difficult for these drugmakers to absorb—and they’d likely have to pass some of those costs along to consumers or stop selling some products altogether, as CNBC reported. “A 100-200% tariff on a product with single-digit margins is a market-exit notice,” Salil Kallianpur, an independent pharmaceutical consultant told the outlet. If the supply of available generic drugs dry up for American consumers, that would likewise increase costs if they’re instead forced to rely on brand-name drugs. As a result, tariffs on generic drugs could end up having the opposite effect than Trump has said he wants to achieve, Nathan Gray, a senior research fellow at the Institute for International Trade at Adelaide University, told Bloomberg.  “If they want to reduce costs for consumers, this is not the way to do it,” Gray told the outlet.  WILL THE DRUGMAKERS MOVE PRODUCTION? There’s also the question of whether Trump’s timeline for reshoring drug manufacturing is even realistic as building new facilities may take longer than a couple years. Trump said in his post that such facilities are being built across the U.S. “at a level never seen before,” though he didn’t provide any specifics regarding that activity. In April, Trump announced a 100% tariff on certain brand-name and patented drugs to effect on July 31 if drugmakers didn’t build factories in the U.S., though several drugmakers were able to avoid those tariffs by negotiating lower prices. Trump said on Tuesday that that policy “has been so successful” that it will remain in place. But because of the economics of generic drugs, many companies may have very little incentive to move manufacturing to the U.S. The Indian Pharmaceutical Alliance, a trade group that represents 23 generic drugmakers, told The Wall Street Journal that tariffs alone wouldn’t lead to sustainable onshoring to the U.S. of generic-medicine production. When the Trump administration started floating the idea of pharmaceutical tariffs last year, the CEO of Sandoz, which makes more than 400 generic drugs, told The Wall Street Journal that such threats wouldn’t induce change—unless the government was willing to offer some help. “Where’s the incentive?” Richard Saynor told the outlet. “You sell a packet of antibiotics more cheaply than a packet of M&M’s. That’s offensive, and we lose money doing that.”

UBS Warns Trump's 100% Generic Drug Tariff Puts Indian Pharma "On Notice"; Goldman Flags Reshoring Winners President Trump will impose a 100% tariff on imported generic drugs starting in August 2028, rising to 200% a year later, unless manufacturers shift production to the US. "This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," Trump wrote on Truth Social late Tuesday. He continued, "The objective of this Policy is to protect the people of the United States. The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is," adding, "Pharmaceutical Facilities are being built, at a level never seen before, all over the United States of America." Trump's announcement is the latest effort to reshore critical supply chains, and in this case, boost domestic production of generic drugs. Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in ‌other high-income countries. At least 90% of medicines sold in the U.S. are generics. UBS analyst Aditi Samajpati told clients earlier that Trump's move to reshore generic drug production puts Indian pharmaceutical companies "on notice." Samajpati said: President Donald Trump has threatened steep tariffs on generic-drug imports to push manufacturing back to the US, though his plan includes a two-year tariff-free window before levies rise to 100% from August 2028 and 200% from August 2029. India is highly exposed: its generic medicines account for nearly 40% of US generic-drug volume, used widely to treat hypertension, diabetes, cancer, and infectious diseases. In FY2024-25, India's pharma exports to the US totalled $9.7bn, according to the Global Trade Research Initiative. Yet implementation is uncertain given prior unfulfilled tariff threats, a February bilateral trade pact that included negotiated outcomes for generics, and India's 30%-50% manufacturing-cost advantage. The risk of immediate disruption is limited as investors assess whether policy pressure can realistically shift low-cost supply chains back to the US, especially if execution stretches beyond Trump's term. Goldman analyst Matt Dellatorre offered clients a way to profit from this announcement: For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA (diversified manufacturing; branded portfolio), and VTRS (diversified manufacturing; limited US exposure). The national security case for reshoring critical generic-drug supply chains stems directly from Covid-era disruptions of essential medicines, active pharmaceutical ingredients, protective equipment, and medical devices. Years of offshoring have left the US dangerously dependent on foreign production, such as that in India. In the event of a future supply shock, particularly one triggered by conflict in the Pacific, Washington could be confronted with shortages far more severe than the Covid-era. Rebuilding domestic production would give the US greater resilience to absorb any future supply shock without jeopardizing access to critical medical supplies. Tyler Durden Wed, 07/22/2026 - 09:45

Indian pharmaceutical stocks came under heavy selling pressure on Wednesday after US President Donald Trump announced a phased tariff plan on generic medicines imported into the United States. The announcement raised concerns over the impact on Indian drugmakers, which are among the largest suppliers of affordable generic medicines to the US market.The Nifty Pharma index declined 1.51% to 25,699.45 by 10:40 am IST. Major pharmaceutical companies, including Sun Pharma, Cipla and Dr Reddy’s Laboratories, traded lower amid concerns over the long-term impact of higher import duties.Cipla and Dr Reddy’s Laboratories were among the biggest losers on the Nifty 50 index, falling 1.8% and 1.6%, respectively. Sun Pharma also remained under pressure, declining 0.9%.Sensex, Nifty Fall Over 0.7% As Crude Oil Surge, Trump Tariffs Hit Sentiment Selling was widespread across the pharmaceutical sector. Lupin dropped nearly 4%, while Piramal Pharma, Aurobindo Pharma and Gland Pharma declined more than 3% each. Other companies including Ajanta Pharma, Glenmark Pharma, IPCA Laboratories, Zydus Lifesciences, Alkem Laboratories and Mankind Pharma also witnessed declines.Trump announced that generic medicines imported into the US would continue to face zero tariffs for two years from August 1, 2026. After this period, tariffs would increase to 100% from August 1, 2028, and rise further to 200% a year later.According to Trump, the tariff policy is intended to encourage pharmaceutical companies to establish manufacturing facilities in the US. He said companies that fail to shift production within the given timeframe would face higher costs, while rules for patented, branded and innovative medicines would remain unchanged. Inside Section 301 Probe That Targets India And 59 Other Countries: Why Washington Is Penalising Trading Partners Over Forced-Labour LoopholesThe move has put Indian pharmaceutical companies under scrutiny due to their strong presence in the US generics market. Firms such as Sun Pharma, Cipla, Dr Reddy’s Laboratories, Lupin, Aurobindo Pharma and Zydus Lifesciences rely heavily on exports to the American market.

Washington: US President Donald Trump on Wednesday announced steep tariffs on imported generic medicines from August 2028, asserting that the move was aimed at onshoring the manufacturing of such pharmaceutical products.Also Watch: The move could affect India, which is the largest exporter of generic drugs to the US.In a post on Truth Social, Trump said beginning August 1, the US will continue to have a zero per cent tariff on all generic drugs brought into the country for two years, after which it will be raised to 100 per cent for one year, and 200 per cent thereafter. - : .. - "Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which… pic.twitter.com/0R5PY2TtAU— Commentary Donald J. Trump Posts From Truth Social (@TrumpDailyPosts) July 21, 2026 "Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for two years, after which the TARIFF will be raised to 100 per cent for one year, and 200 per cent thereafter," Trump said.The Government Must Make Life-Saving Medicines Affordable For The Common Man "This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them," Trump said.The president said the objective of this policy is to protect the people of the United States.Centre Withdraws Licensing Exemption For High-Alcohol Medicinal Formulations, Mandates Prescription-Only Sale "The Policy on Patented, Branded, or Innovative Drugs, which has been so successful, will remain as is," he said.India is often called the “pharmacy of the world” as it supplies generic medicines to countries across the globe.Maha Govt To Ensure All Essential Medicines Available At State Hospitals In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion, a Global Trade Research Initiative report said.Indian generic medicines are widely prescribed for hypertension, diabetes, cancer, infectious diseases, and mental health. (Except for the headline, this article has not been edited by FPJ's editorial team and is auto-generated from an agency feed.)